UBS Group’s Cellectar Biosciences CLRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.6K | Sell |
3,093
-6,554
| -68% | -$18.3K | ﹤0.01% | 8661 |
|
|
2026
Q1 | $24.5K | Buy |
9,647
+7,049
| +271% | +$22.7K | ﹤0.01% | 7805 |
|
|
2025
Q4 | $7.66K | Buy |
2,598
+1,690
| +186% | +$6.24K | ﹤0.01% | 8427 |
|
|
2025
Q3 | $5.08K | Sell |
908
-2,712
| -75% | -$13.4K | ﹤0.01% | 8901 |
|
|
2025
Q2 | $25.7K | Sell |
3,620
-27,058
| -88% | -$237K | ﹤0.01% | 8277 |
|
|
2025
Q1 | $290K | Buy |
30,678
+18,138
| +145% | +$164K | ﹤0.01% | 6276 |
|
|
2024
Q4 | $112K | Buy |
12,540
+12,454
| +14,481% | +$576K | ﹤0.01% | 6795 |
|
|
2024
Q3 | $5.51K | Sell |
86
-407
| -83% | -$26.8K | ﹤0.01% | 8048 |
|
|
2024
Q2 | $37K | Buy |
493
+295
| +149% | +$28.3K | ﹤0.01% | 6919 |
|
|
2024
Q1 | $23.7K | Buy |
198
+158
| +395% | +$17.1K | ﹤0.01% | 6850 |
|
|
2023
Q4 | $3.32K | Sell |
40
-2
| -5% | -$149 | ﹤0.01% | 7989 |
|
|
2023
Q3 | $3.32K | Buy |
42
+2
| +5% | +$118 | ﹤0.01% | 7577 |
|
|
2023
Q2 | $2.34K | Sell |
40
-30
| -43% | -$1.44K | ﹤0.01% | 7765 |
|
|
2023
Q1 | $3.02K | Buy |
70
+15
| +27% | +$731 | ﹤0.01% | 8400 |
|
|
2022
Q4 | $2.82K | Hold |
55
| – | – | ﹤0.01% | 9620 |
|
|
2022
Q3 | $6K | Sell |
55
-77
| -58% | -$11.1K | ﹤0.01% | 9010 |
|
|
2022
Q2 | $16K | Buy |
132
+77
| +140% | +$11K | ﹤0.01% | 7182 |
|
|
2022
Q1 | $11K | Sell |
55
-118
| -68% | -$20.7K | ﹤0.01% | 8287 |
|
|
2021
Q4 | $34K | Buy |
173
+135
| +355% | +$32.5K | ﹤0.01% | 7256 |
|
|
2021
Q3 | $11K | Hold |
38
| – | – | ﹤0.01% | 7867 |
|
|
2021
Q2 | $14K | Buy |
38
+31
| +443% | +$13.4K | ﹤0.01% | 7698 |
|
|
2021
Q1 | $3K | Buy |
7
+2
| +40% | +$1.19K | ﹤0.01% | 8505 |
|
|
2020
Q4 | $3K | Buy |
+5
| New | +$2.3K | ﹤0.01% | 7988 |
|
|
2020
Q3 | – | Sell |
-4
| Closed | -$1K | – | 8023 |
|
|
2020
Q2 | $1K | Buy |
4
+2
| +100% | +$840 | ﹤0.01% | 7746 |
|
|
2020
Q1 | $1K | Buy |
+2
| New | +$1.34K | ﹤0.01% | 7745 |
|
|
2019
Q1 | – | Sell |
-19
| Closed | -$9K | – | 7767 |
|
|
2018
Q4 | $9K | Buy |
19
+11
| +138% | +$7.83K | ﹤0.01% | 7273 |
|
|
2018
Q3 | $8K | Buy |
+8
| New | +$9.42K | ﹤0.01% | 7266 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 8003 |
|
|
2018
Q1 | – | Sell |
-3
| Closed | -$10.7K | – | 7842 |
|
|
2017
Q4 | $13K | Buy |
+3
| New | +$13.4K | ﹤0.01% | 6856 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | -$4.85K | – | 7740 |
|
|
2017
Q2 | $4K | Buy |
+1
| New | +$5.48K | ﹤0.01% | 7198 |
|
|
2016
Q3 | – | Sell |
-3
| Closed | -$35K | – | 7690 |
|
|
2016
Q2 | $35K | Buy |
3
+2
| +200% | +$16.7K | ﹤0.01% | 5801 |
|
|
2016
Q1 | $7K | Buy |
+1
| New | +$15.5K | ﹤0.01% | 6842 |
|
|
2015
Q4 | – | Hold |
0
| – | -$9K | – | 8359 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 7325 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 7959 |
|
Other funds holding CLRB
VCM
SCM
BL
EAM
PAP
VFT
SFA
RCA
UBS Group's CLRB Position: Q2 2026 in Review
UBS Group reduced its Cellectar Biosciences (CLRB) stake by 68% in Q2 2026, selling an estimated $18.3K and leaving 3,093 shares worth $8.6K. The position accounts for ﹤0.01% of the portfolio, ranked #8661.
UBS Group first reported a position in CLRB in Q1 2016 and has held it in 31 quarters since. The position peaked at $290K in Q1 2025. 18 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.
- UBS Group held 3,093 shares of Cellectar Biosciences worth $8.6K as of Q2 2026.
- UBS Group sold 6,554 Cellectar Biosciences shares in Q2 2026, an estimated $18.3K.
- Cellectar Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8661 holding.
- UBS Group first reported a position in Cellectar Biosciences in Q1 2016 and has held it in 31 quarters since.
- UBS Group's Cellectar Biosciences position peaked at $290K in Q1 2025.
- 18 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.